Profluent utilizes artificial intelligence to author novel proteins for diverse applications. Their platform designs custom protein sequences, including AI-designed gene editors like OpenCRISPR. This capability enables the creation of new solutions across therapeutics, agriculture, and industrial enzyme development.
Funding
$44M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional protein design and validation methods are slow, expensive, and often yield proteins with limited functionality or stability. This inefficiency hinders the development of novel therapeutics and other biomedicine applications that rely on custom-engineered proteins.
Solution
Profluent leverages deep generative models to accelerate the design and validation of novel proteins. By applying advanced AI techniques to decode the underlying principles of protein structure and function, Profluent's platform enables the creation of proteins with enhanced properties and tailored functionalities. This approach significantly reduces the time and resources required for protein engineering, facilitating the development of innovative therapeutic solutions. The platform aims to overcome the limitations of traditional methods by predicting and optimizing protein sequences for desired characteristics, such as improved binding affinity, stability, or enzymatic activity.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery, protein engineering, and other biomedicine applications.
Features
- Deep generative models for de novo protein sequence design
- AI-driven prediction of protein structure and function
- In silico validation of protein candidates
- Optimization of protein sequences for desired properties
- High-throughput screening capabilities